CD274 and cancer: A study by Hong et al. analysed 112 cancer patients for which PD-L1 expression was assessed at two different time points during the disease course, of which 77 received treatment (radiotherapy, surgery, chemotherapy, EGFR or ALK tyrosine kinase inhibitor or ICB) between biopsies.